Prevalence of salivary anti‐SARS‐CoV‐2 IgG antibodies in vaccinated children

ImmunologyVolume 169, Issue 3 p. 384-387 LETTER TO THE EDITOR Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children María Noel Badano, Corresponding Author María Noel Badano [email protected] orcid.org/0000-0002-0358-7738 Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires, Argentina Correspondence María Noel Badano, Laboratorio de Patogenia de Infecciones Virales, Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina. Email: [email protected]Search for more papers by this authorAlejandra Duarte, Alejandra Duarte orcid.org/0000-0002-1487-8354 Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorGabriela Salamone, Gabriela Salamone orcid.org/0000-0002-0438-1942 Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorFlorencia Sabbione, Florencia Sabbione Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorMatias Pereson, Matias Pereson Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, ArgentinaSearch for more papers by this authorRoberto Chuit, Roberto Chuit Instituto de Investigaciones Epidemiológicas (IIE), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorPatricia Baré, Patricia Baré Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this author María Noel Badano, Corresponding Author María Noel Badano [email protected] orcid.org/0000-0002-0358-7738 Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires, Argentina Correspondence María Noel Badano, Laboratorio de Patogenia de Infecciones Virales, Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina. Email: [email protected]Search for more papers by this authorAlejandra Duarte, Alejandra Duarte orcid.org/0000-0002-1487-8354 Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorGabriela Salamone, Gabriela Salamone orcid.org/0000-0002-0438-1942 Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorFlorencia Sabbione, Florencia Sabbione Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorMatias Pereson, Matias Pereson Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, ArgentinaSearch for more papers by this authorRoberto Chuit, Roberto Chuit Instituto de Investigaciones Epidemiológicas (IIE), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this authorPatricia Baré, Patricia Baré Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires, ArgentinaSearch for more papers by this author First published: 15 May 2023 https://doi.org/10.1111/imm.13656 Alejandra Duarte and Gabriela Salamone contributed equally to this research. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Ketas TJ, Chaturbhuj D, Portillo VMC, Francomano E, Golden E, Chandrasekhar S, et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. Pathog Immun. 2021; 6(1): 116–34. https://doi.org/10.20411/pai.v6i1.441 2Healy K, Pin E, Chen P, Söderdahl G, Nowak P, Mielke S, et al. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med (N Y). 2022; 3(2): 137–153.e3. https://doi.org/10.1016/j.medj.2022.01.001 3Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022; 386(1): 35–46. https://doi.org/10.1056/NEJMoa2116298 4Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021; 385(3): 239–50. https://doi.org/10.1056/NEJMoa2107456 5Xia S, Zhang Y, Wang Y, Wang H, Yang YK, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2022; 22(2): 196–208. https://doi.org/10.1016/S1473-3099(21)00462-X 6Badano MN, Pereson MJ, Sabbione F, Keitelman I, Aloisi N, Chuit R, et al. SARS-CoV-2 breakthrough infections after third doses boost IgG specific salivary and blood antibodies. Vaccines. 2023; 11:534. https://doi.org/10.3390/vaccines11030534 7Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature. 2022; 602(7898): 664–70. https://doi.org/10.1038/s41586-021-04386-2 Volume169, Issue3July 2023Pages 384-387 ReferencesRelatedInformation